Arcus Biosciences Inc (RCUS)
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapies in the United States. Its pipeline includes casdatifan, a HIF-2a inhibitor being developed for kidney cancer; domvanalimab, an anti-TIGIT antibody in Phase 2 and Phase 3 studies for lung and gastrointestinal cancers; and zimberelimab, an anti-PD-1 antibody. The company is also advancing quemliclustat, a CD73-targeting small-molecule inhibitor in Phase 3 and Phase 1/1b trials for lung and pancreatic cancer, along with AB598, a CD39 antibody in Phase 1/1b studies for gastrointestinal cancer, and AB801, an AXL inhibitor in Phase 1b testing for lung cancer. Arcus Biosciences has collaboration agreements with AstraZeneca for PACIFIC-8 and a separate study in ccRCC, as well as with BVF Partners L.P. to support research in inflammatory diseases. The company was incorporated in 2015 and is headquartered in Hayward, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-RCUS
|
$24.53
|
-8.7% Downside
|
Fair
|
$38.75
|
44.2% Upside
|
Undervalued
|
Weak
|
0.0%
|
November 10, 2026
|
7.4x
|
29.2x
|
3.421 B
|
2.884 B
|
6.7%
|
71.1%
|
0.8
|
103.3%
|
